extracorporeal

Home>Tag: extracorporeal
Jun 30 2021

Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process

By |2021-06-29T23:00:53-04:00June 30th, 2021|Featured, Investor News, News|0 Comments

Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies.  This simplified method for the removal of disease-causing antigen(s) utilizes more conventional ...

Jun 21 2021

Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

By |2021-06-20T21:56:56-04:00June 21st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means.  Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to ...

Jun 16 2021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

By |2021-06-15T21:04:24-04:00June 16th, 2021|Featured, Investor News, News|0 Comments

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process.  These three antigens, which are found in Cerebral Spinal ...

Jun 7 2021

Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies

By |2021-06-06T20:44:05-04:00June 7th, 2021|Featured, Investor News, News|0 Comments

Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19.  Each of these new antibodies bind to different ...

Jun 1 2021

Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects

By |2021-05-30T12:12:26-04:00June 1st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 1, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a U. S. joint provisional patent application titled, “Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2.”  The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University (ASU).  The provisional patent application covers technology developed to ...

May 25 2021

Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody

By |2021-05-24T21:12:58-04:00May 25th, 2021|Featured, Investor News, News|0 Comments

Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody.  This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By |2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein.  This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

May 13 2021

Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease

By |2021-05-12T20:19:30-04:00May 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 13, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease.  This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications.  The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of ...

Apr 19 2021

Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward With the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus

By |2021-04-18T21:39:58-04:00April 19th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Brings Critical Radio Frequency Wave Expertise to Company’s Effort Jackson Center, PA, April 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. William G. Sturrus will lead the Radio Frequency (RF) research on Halberd’s Disease Elimination multi-organization Task Force.  Dr. Sturrus, who has 30 years of radio ...

Apr 12 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

By |2021-04-11T20:02:28-04:00April 12th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 12, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Covid-19 Inflammatory Cytokine Storm Treatment.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. Hartman, Chairman, ...

Go to Top